Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics Q3 2024 Earnings Report

MoonLake Immunotherapeutics logo
$39.04 -2.87 (-6.85%)
As of 01:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.12
One Year Ago EPS
-$0.18

MoonLake Immunotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MoonLake Immunotherapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

MoonLake Immunotherapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025

Earnings Documents

MoonLake Immunotherapeutics Earnings Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More MoonLake Immunotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MoonLake Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MoonLake Immunotherapeutics and other key companies, straight to your email.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

View MoonLake Immunotherapeutics Profile

More Earnings Resources from MarketBeat